Moving toward personalized B cell depletion in multiple sclerosis?

Tradite Neziraj; Ludwig Kappos; Anne-Katrin Pröbstel

doi:10.1016/j.medj.2023.05.006

Moving toward personalized B cell depletion in multiple sclerosis?

Med. 2023 Jun 9;4(6):344-346. doi: 10.1016/j.medj.2023.05.006.

Authors

Tradite Neziraj¹, Ludwig Kappos², Anne-Katrin Pröbstel³

Affiliations

¹ Department of Neurology, University Hospital of Basel and University of Basel, Basel, Switzerland; Departments of Biomedicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland.
² Departments of Biomedicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland; Department of Biomedical Engineering, University Hospital of Basel and University of Basel, Basel, Switzerland.
³ Department of Neurology, University Hospital of Basel and University of Basel, Basel, Switzerland; Departments of Biomedicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital of Basel and University of Basel, Basel, Switzerland. Electronic address: anne-katrin.proebstel@usb.ch.

PMID: 37301194
DOI: 10.1016/j.medj.2023.05.006

Abstract

B cell depletion is becoming a preferred long-term treatment even in early multiple sclerosis, but concerns about the risks of impaired immune competence persist. In their observational study Schuckmann et al. thoroughly assessed the impact of B cell-adapted extended interval dosing on immunoglobulin levels as a surrogate of adverse immunosuppressive effects.

Publication types

Observational Study

MeSH terms

B-Lymphocytes
Humans
Immunosuppressive Agents / therapeutic use
Multiple Sclerosis* / therapy

Substances

Immunosuppressive Agents